Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02641093 · ClinicalTrials.gov registry record · Phase 2

Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma

A Phase 2 study of Head and Neck Cancer, sponsored by Trisha Wise-Draper.

Active
Registry status
Phase 2
Development phase
96
Enrollment target
6
Study locations

NCT02641093 is a Phase 2 study of Head and Neck Cancer that is active but no longer recruiting, run by Trisha Wise-Draper. The registered enrollment target is 96 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (63% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02641093, a Phase 2 study of Head and Neck Cancer, is active but no longer recruiting, sponsored by Trisha Wise-Draper.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
96 participants
Enrollment target
6
Study locations

Study Summary

The purpose of this research study is to test the safety and the benefit of adding pembrolizumab (a therapy that activates the immune system to fight cancer) to standard of care treatment for head and neck cancer. The standard of care treatment will include surgery followed by radiation for 6 weeks. Some patients may also receive cisplatin as standard of care once a week for 6 weeks if the cancer is found to be "high risk". High risk includes cancer that was not completely removed (positive margins) or cancer that has invaded through the outer lining of your lymph nodes.

Conditions Studied

Head and Neck Cancer

Interventions

  • DRUG Pembrolizumab
  • DRUG Cisplatin
  • RADIATION Radiation Therapy
  • PROCEDURE Surgery

Study Locations (6)

Ohio

  • University of Cincinnati Medical Center - Cincinnati
  • Ohio State University - Columbus

Kentucky

  • University of Louisville - James Graham Brown Cancer Center - Louisville

Michigan

  • University of Michigan - Ann Arbor

South Carolina

  • Medical University of South Carolina - Charleston

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2016-01
Est. Completion 2025-11-02
Phase Phase 2

Sponsor

Trisha Wise-Draper

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02641093

The ClinicalTrials.gov registry entry for NCT02641093 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (63% lower). The listed sponsor is Trisha Wise-Draper, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT02641093 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Ohio, Kentucky, Michigan.

Frequently Asked Questions

What is clinical trial NCT02641093 about?

NCT02641093 is a clinical study titled "Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma". The purpose of this research study is to test the safety and the benefit of adding pembrolizumab (a therapy that activates the immune system to fight cancer) to standard of care treatment for head and neck cancer. The standard of care treatment will include surgery followed by radiation for 6 weeks....

What is the current status of trial NCT02641093?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2016-01. Estimated completion is 2025-11-02.

What conditions does trial NCT02641093 study?

This clinical trial studies the following conditions: Head and Neck Cancer.

What interventions are being tested in trial NCT02641093?

The interventions under investigation include: Pembrolizumab (DRUG), Cisplatin (DRUG), Radiation Therapy (RADIATION), Surgery (PROCEDURE).

Who is sponsoring clinical trial NCT02641093?

This trial is sponsored by Trisha Wise-Draper, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02641093 being conducted?

This trial has 6 study locations across Kentucky, Michigan, Ohio, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Head and Neck Cancer

All registered trials for this condition

Kentucky

All trials with a study site in Kentucky

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.